Fenugreek exhibits hypocholesterolemic, hypolipidemic, and hypoglycemic activity in healthy and diabetic animals and humans (1) (2). The mechanism is uncertain, but its activity may be associated with the galactomannan fiber and saponin components that reduce gastrointestinal glucose and cholesterol absorption and increase bile acid excretion (14). Hypoglycemic activity is also attributed to the trigonelline, nicotinic acid, and coumarin fractions. 4-Hydroxyisoleucine, an amino acid constituent of fenugreek, potentiates insulin secretion in NIDDM rats when administered intraperitoneally (15). Fenugreek intake in humans is associated with an increase in molar insulin binding sites of erythrocytes, which may enhance glucose utilization (16). In addition to lower fasting and postprandial glucose levels, fenugreek-treated diabetic rats have higher hemoglobin, GSH, and plasma antioxidant levels and lower glycosylated hemoglobin, plasma lipids, and TBARS levels than diabetic controls (4). Dietary fenugreek normalizes the activities of glucose and lipid-metabolizing enzymes in diabetic rats (3). In healthy mice and rats, dietary fenugreek is associated with increased serum T4, liver GSH, glyoxalase I, and GST activities, and decreased T3 levels and T3/T4 ratio (17) (18) (19). Extracts of fenugreek show antimicrobial and nematocidal activity in vitro (20). In MCF-7 estrogen receptor-positive breast cancer cells, fenugreek extract induces cell cycle arrest as well as apoptosis (9).